Tonix Pharmaceuticals Holding Corp.
TNXPNASDAQHealthcareBiotechnology
Previous close
$12.55
+$0.16 · +1.29%
TNXP company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
88
Deep Value
Momentum
34
Weakening
Sentiment
73
Bullish
Risk resilience
26
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteTonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Seth Lederman
- Listed since
- May 10, 2012
- Employees
- 142
Market position
Day range
Current $12.55
52-week range
Current $12.55
- Open
- $12.68
- Previous close
- $12.39
- Volume
- 369.68K
- 0.75× average
- Average volume
- 492.27K
- Average daily volume
- Market cap
- 200.06M USD
- Beta
- 1.69
- Market reference 1
- 50-day average
- $11.78
- +6.54% above average
- 200-day average
- $14.2907
- -12.18% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- -73.38M USD
- P/E (TTM)
- -0.95×
- P/B (TTM)
- 0.94×
- P/S (TTM)
- 6.87×
- EV / EBITDA
- 0.6×
- Earnings yield
- -93.29%
- Free cash flow yield
- -77.63%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 80.25%
- Operating margin
- -568.43%
- Net margin
- -548.64%
- Return on equity
- -50.59%
- Return on assets
- -44.75%
- Return on invested capital
- -51.00%
Financial health
- Debt / equity
- 0.01×
- Current ratio
- 7.42×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 13.11M USD | 10.09M USD | 7.77M USD | — | — |
| Cost of goods sold | 8.57M USD | 7.77M USD | 4.74M USD | — | — |
| Gross profit | 4.54M USD | 2.33M USD | 3.03M USD | — | — |
| Research and development | 44.49M USD | 40.45M USD | 86.66M USD | 81.88M USD | 68.84M USD |
| Selling, general, and administrative | 85.76M USD | 40.1M USD | 34.75M USD | 30.22M USD | 23.47M USD |
| Operating expenses | 130.25M USD | 139.03M USD | 121.41M USD | 112.09M USD | 92.31M USD |
| Interest income | 4.15M USD | — | — | 1.87M USD | 25K USD |
| Interest expense | 89K USD | — | — | — | — |
| Depreciation and amortization | 1.93M USD | 3.42M USD | 4.29M USD | 1.25M USD | 50K USD |
| Operating income | −125.7M USD | −136.7M USD | −118.38M USD | −112.09M USD | −92.31M USD |
| Net income | −124.02M USD | −130.04M USD | −116.66M USD | −110.22M USD | −92.29M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 45%
- 5 beats, 5 misses, 1 met estimate
- Average EPS surprise
- -38.28%
- 11 comparable reports
- Latest EPS result
- -2.44
- Estimate -2.64 · Beat by 7.58%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$27.00
115.14% upsideRating distribution
7 ratingsRecent analyst actions
TNXP news
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Feb 5, 2025 | 1:100 | — | — |
Stock split | Jun 10, 2024 | 1:32 | — | — |
Stock split | May 10, 2023 | 4:25 | — | — |
Stock split | May 17, 2022 | 1:32 | — | — |
Stock split | Nov 1, 2019 | 1:10 | — | — |
Stock split | Nov 28, 2018 | 1:10 | — | — |
Effective Feb 5, 2025
1:100
Effective Jun 10, 2024
1:32
Effective May 10, 2023
4:25
Effective May 17, 2022
1:32
Effective Nov 1, 2019
1:10
Effective Nov 28, 2018
1:10
TNXP peers
ETFs holding TNXP
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI4.89M0.00%2.3T USD0.03%$378.24+0.44%
iShares Russell 2000 ETFIWM4.76M0.01%81.62B USD0.19%$299.96+0.77%
Fidelity Enhanced Small Cap ETFFESM2.36M0.04%6.03B USD0.28%$47.94+0.80%
Vanguard Extended Market ETFVXF1.88M0.00%93.7B USD0.05%$245.53+0.82%
iShares Russell 2000 Value ETFIWN1.79M0.01%14.66B USD0.24%$224.81+0.45%
Vanguard Russell 2000 ETFVTWO824.77K0.00%17.4B USD0.06%$121.25+0.74%
iShares Micro-Cap ETFIWC631.06K0.04%1.53B USD0.60%$198.39+1.10%
Invesco RAFI US 1500 Small-Mid ETFPRFZ267.17K0.01%2.87B USD0.34%$55.89+0.87%Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 4.89M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
iShares Russell 2000 ETFIWM- Market value
- 4.76M
- Weight
- 0.01%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $299.96+0.77%
Fidelity Enhanced Small Cap ETFFESM- Market value
- 2.36M
- Weight
- 0.04%
- AUM
- 6.03B USD
- Expense ratio
- 0.28%
- Price / 1D
- $47.94+0.80%
Vanguard Extended Market ETFVXF- Market value
- 1.88M
- Weight
- 0.00%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
iShares Russell 2000 Value ETFIWN- Market value
- 1.79M
- Weight
- 0.01%
- AUM
- 14.66B USD
- Expense ratio
- 0.24%
- Price / 1D
- $224.81+0.45%
Vanguard Russell 2000 ETFVTWO- Market value
- 824.77K
- Weight
- 0.00%
- AUM
- 17.4B USD
- Expense ratio
- 0.06%
- Price / 1D
- $121.25+0.74%
iShares Micro-Cap ETFIWC- Market value
- 631.06K
- Weight
- 0.04%
- AUM
- 1.53B USD
- Expense ratio
- 0.60%
- Price / 1D
- $198.39+1.10%
Invesco RAFI US 1500 Small-Mid ETFPRFZ- Market value
- 267.17K
- Weight
- 0.01%
- AUM
- 2.87B USD
- Expense ratio
- 0.34%
- Price / 1D
- $55.89+0.87%
Continue in GoAI
Research TNXPresearch.disclaimer